Difference between revisions of "Pharm Tech Minutes 2021.06.23"

From IHE Wiki
Jump to: navigation, search
(Welcome)
(Any other business)
 
(10 intermediate revisions by the same user not shown)
Line 16: Line 16:
 
== Medication lists ==
 
== Medication lists ==
  
* Sandbox Belgium  
+
* Focus on the Sandbox which Jose has used for Belgium  
 
* A patient has a treatment plan. This could initiated by the patient, but more often it could be a plan from a Care Provider.  
 
* A patient has a treatment plan. This could initiated by the patient, but more often it could be a plan from a Care Provider.  
 
* There could be multiple plans from different care providers.  
 
* There could be multiple plans from different care providers.  
* The diagram is actually treatment centric.  
+
* The diagram is actually treatment.  
* Agreement that there is a treatment, but difference is where to draw the line.  
+
* Agreement in the group that there is a treatment, but difference is where to draw the line.  
* In the NL the treatment line is part of the prescription and the prescription  is similar with the supply request.
+
* The rules where to find the correct dosage will depend on the settings in the different countries.
* the rules where to find the correct dosage will depend on the settings in the different countries.
+
* Rules to the period will differ per country. A current medication summary in NL& F means the last 6 months. In Switzerland it is what the patient is using now. Point is that we would like to define the differences.
* rules to the period will differ per country. A current medication summary in NL means the last 6 months. In Switzerland it is what the patient is using now. Point is that we would like to define the differences.
+
* Within FHIR it makes it easier to map to another format from another country. The IHE profile would make the mapping much easier.
 +
* The IPS is just a collection of medication statements.
 +
* We should not use the same name as IPS. Suggestion to use '''medication view'''.
 +
* Indication is mentioned on different levels. It also depends on the setting where to mention the indication.
 +
 
 +
* Action items for the F2F in September:
 +
** generic guidelines to be written ( Stephane)
 +
** Mapping to different country settings. Belgium, Switzerland, Netherlands, France, Austria. (all other members)
  
 
== Any other business ==
 
== Any other business ==
 +
 +
* Links:
 +
** http://build.fhir.org/ig/hl7-be/riziv-inami/artifacts.html
 +
** http://build.fhir.org/ig/hl7-be/riziv-medication-record/medicationrecord-fhir-resources.html

Latest revision as of 04:00, 25 June 2021

Minutes

Welcome

  • Participants
    • Jose Costa Teixeira
    • Stephane Spahni
    • Michael Tan
    • Juergen Brandstaetter
    • Marc Robberecht


  • Review and Approve Agenda

Medication lists

  • Focus on the Sandbox which Jose has used for Belgium
  • A patient has a treatment plan. This could initiated by the patient, but more often it could be a plan from a Care Provider.
  • There could be multiple plans from different care providers.
  • The diagram is actually treatment.
  • Agreement in the group that there is a treatment, but difference is where to draw the line.
  • The rules where to find the correct dosage will depend on the settings in the different countries.
  • Rules to the period will differ per country. A current medication summary in NL& F means the last 6 months. In Switzerland it is what the patient is using now. Point is that we would like to define the differences.
  • Within FHIR it makes it easier to map to another format from another country. The IHE profile would make the mapping much easier.
  • The IPS is just a collection of medication statements.
  • We should not use the same name as IPS. Suggestion to use medication view.
  • Indication is mentioned on different levels. It also depends on the setting where to mention the indication.
  • Action items for the F2F in September:
    • generic guidelines to be written ( Stephane)
    • Mapping to different country settings. Belgium, Switzerland, Netherlands, France, Austria. (all other members)

Any other business